Eli Lilly Establishes Partnership With AC Immune For Alzheimer’s Drug Worth Up To $2 Billion

Eli Lilly and AC Immune (ACIU) are establishing a partnership to obtain a drug for the treatment of Alzheimer’s disease, worth up to $2 billion. Eli Lilly will pay ACIU an initial $80 million upfront, with more payments coming as certain milestones are met in the creation of the drug, which is currently only in pre-clinical stages of testing.

Eli Lilly continues its efforts despite having a significant setback in 2016, when it announced a phase 3 trial failure for its anti-amyloid drug, Solanezumab. Its new collaboration with ACIU comes as several pharmaceutical companies attempt to create . . .